[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588377":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":56,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of New Mexico","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sham accelerated iTBS","SHAM_COMPARATOR","Sham stimulation is delivered using the same coil as active stimulation, producing an equivalent sound, however it is shielded so that no effective magnetic field reaches the participant's brain. To blind participants to active versus sham condition, a mild electrical skin stimulation that has no brain effects is delivered simultaneously with iTBS at the scalp to both active and sham groups, creating the same sense of skin sensation in both groups.",[13],"Device: accelerated intermittent theta burst stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Active accelerated iTBS","EXPERIMENTAL","Participants will be assigned to receive fMRI-guided iTBS (5 days, 5 sessions\u002Fday) to the left dorsolateral prefrontal cortex (dlPFC) during the sham-controlled phase. Each participant is invited to undergo 25 more sessions (5 more days) of open label, unblinded active accelerated fMRI-guided iTBS to the left dlPFC.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","accelerated intermittent theta burst stimulation","Intermittent theta burst stimulation (iTBS), a FDA-approved form of noninvasive neuromodulation, can reduce neuropsychiatric symptoms and modulate inflammation in the thalamus as detected using dMRS, suggesting a potentially effective and efficient treatment approach with a pathophysiological component that is readily quantifiable.",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Davin Quinn, MD","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Crystal Garcia","CONTACT","505-272-9552","crabaca@salud.unm.edu",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of New Mexico Health Science Center","RECRUITING","Albuquerque","New Mexico","87106","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-106.65114,35.08449,{"lat":49,"lon":48},[52,53],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"name":28,"role":29,"phone":25,"phoneExt":25,"email":25},{"type":55,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[57,59],{"name":58,"class":6},"The Mind Research Network",{"name":60,"class":61},"United States Department of Defense","FED","100588377","phase-2-magnetic-resonance-analysis-of-neural-inflammatory-factors-and-external-stimulation-100588377",false,"NCT06940609","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation","Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)","MANIFEST","Inclusion Criteria:\n\n1. aged 18-80\n2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List\n3. have \"brain fog\" or cognitive difficulties as one of the ongoing symptoms\n4. are fluent in English\n5. if taking psychotropic medications, have been on stable doses for the past month.\n\nExclusion Criteria:\n\n1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms;\n2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation\n3. history of ongoing substance\u002Falcohol dependence, to reduce confounding effects on diagnosis and brain imaging\n4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS\n5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study\n6. any condition that would prevent the subject from completing the protocol\n7. appointment of a legal representative, to avoid coercion of a vulnerable population\n8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings\n9. any contraindication to MRI\n10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.","ALL","18 Years","80 Years",{"count":74,"type":75},60,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are:\n\n* Is iTBS effective and feasible for reducing Long COVID symptoms? We will measure these symptoms using the Symptom Burden Questionnaire.\n* Are there changes in inflammatory brain chemicals associated with treatment with iTBS? We will be looking at levels of choline in the brain, which is thought to be related to inflammation.\n\nResearchers will compare sham versus active forms of iTBS to see if the active group has greater improvement in symptoms.\n\nParticipants will complete symptom surveys, cognitive tests, and magnetic resonance imaging scans at the beginning, middle, and end of treatment.",[81,82,83,84,85],"Long COVID","Long COVID Syndrome","Long COVID-19 Syndrome","PASC","PASC Post Acute Sequelae of COVID 19","2025-07-11",{"date":88,"type":89},"2025-07-15","ACTUAL",{"date":91,"type":89},"2025-07-07",{"date":93,"type":75},"2029-06-30",{"name":5,"class":6},1]